ArticleMovement disorders : official journal of the Movement Disorder Society2025
Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease.
Article in Movement disorders : official journal of the Movement Disorder Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Roseburia intestinalis Offers Vagus-Dependent Neuroprotection Against Parkinson's Disease.Molecular neurobiology · 2026Article
- Cerebrospinal fluid dopamine 3-O-sulfate as a novel biomarker for predicting motor complications in Parkinson's disease: insights from the PPMI cohort.Journal of translational medicine · 2026Article
- Plasma Levels of Food-Derived Metabolites as Biomarkers of Parkinson's Disease.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe long prodromal phase of Parkinson's disease (PD) and the link the disease has with metabolic factors suggest that metabolomics could help identify affected individuals at early stages.
objectiveThe goal was to examine whether plasma metabolomic profiles could identify individuals in the prodromal and clinical phase of PD.
methodsWe quantified and compared the plasma metabolomic profiles of 922 individuals with PD who provided blood samples at a median of 11 years before (n = 809) or 2 years after (n = 113) disease diagnosis to that of matched controls, all selected from three established cohort studies (Nurses' Health Study, Health Professionals Follow-up Study, and Cancer Prevention Study II). We used conditional logistic regression models and machine learning techniques to identify metabolites predicting prodromal and clinically manifest PD.
resultsSeveral metabolites, especially amino acids, acyl-carnitines, and other lipids were nominally associated with PD since the years leading to disease diagnosis. Metabolites proposed as biomarkers of foods or care products tended to be associated with a higher PD risk closer to disease diagnosis. Metabolites reflecting higher intake of coffee, smoking, and acetaminophen tended to be associated with a lower PD risk over the course of the disease. Metabolomic profiles in prodromal samples were unable to accurately predict future clinical PD.
conclusionsMetabolic pathways related to the metabolism of amino acids and lipids may be involved in PD progression. Metabolomic differences may also result from behavioral changes and medical management, emphasizing the need to consider prodromal and clinical data in future studies. © 2025 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.